Loading
Cholangiocarcinoma and Gallbladder Cancer Studies / Liver Diseases and Immunity / Gallbladder and Bile Duct Disorders · Journal article
Cancer Immunology Immunotherapy · August 10, 2026
Encouraging direction, but not yet definitive.
This multicenter retrospective cohort study reports that sintilimab and lenvatinib combined with locoregional therapy improved median PFS and OS compared to chemotherapy-based first-line regimens in advanced intrahepatic cholangiocarcinoma, with manageable safety. The non-randomized design and modest sample size require prospective validation before clinical adoption.
Multicenter retrospective cohort study. Patients with advanced intrahepatic cholangiocarcinoma receiving first-line treatment; setting and eligibility criteria not specified.. Intervention: Sintilimab plus lenvatinib combined with locoregional therapy (external beam radiation therapy, hepatic arterial infusion chemotherapy, or transarterial chemoembolization).. Compared with: Immune checkpoint inhibitors plus chemotherapy, or chemotherapy alone.. n = 169. Multicenter; specific countries or regions not stated..
Median PFS 11.9 months (triple-regimen) vs 6.0 months (ICIs-chemo, P<0.001) vs 5.2 months (chemotherapy, P=0.007) Median OS 18.7 months (triple-regimen) vs 14.4 months (ICIs-chemo, P=0.044) vs 13.4 months (chemotherapy, P=0.036) ORR 53.3% with triple-regimen vs 25.0% with ICIs-chemo and 28.1% with chemotherapy
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The observed survival gains (median OS 4.3 months over chemotherapy alone, 4.6 months longer than ICIs-chemo) are clinically meaningful if confirmed in a randomized trial. Clinicians should await prospective evidence before adopting this triple-combination as standard first-line therapy, but the safety profile supports further investigation.
A multicenter retrospective study showing improved survival and response rates with triple-combination therapy in advanced ICC, but limited by non-randomized design and moderate sample size that requires prospective confirmation.
As stated by the source record.
Quoted from the source exactly as published.
The observed survival gains (median OS 4.3 months over chemotherapy alone, 4.6 months longer than ICIs-chemo) are clinically meaningful if confirmed in a randomized trial. Clinicians should await prospective evidence before adopting this triple-combination as standard first-line therapy, but the safety profile supports further investigation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Chemotherapy, alone or combined with immune checkpoint inhibitors (ICIs), remains the standard first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC), but survival gains are modest. Triple-combination strategies integrating targeted therapy, ICIs, and locoregional treatment have shown promise in biliary tract cancer, yet sintilimab-based regimens have not been systematically evaluated. This study assessed the efficacy and safety of sintilimab plus lenvatinib and locoregional therapy (triple-regimen) in advanced ICC. In this multicenter retrospective study, 169 patients with advanced ICC received triple-regimen, ICIs plus chemotherapy (ICIs-chemo), or chemotherapy alone between October 2019 and June 2025. Locoregional modalities included external beam radiation therapy, hepatic arterial infusion chemotherapy, and transarterial chemoembolization. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs). The triple-regimen was associated with improved survival versus both comparators. Median PFS was 11.9 months with triple-regimen versus 6.0 months with ICIs-chemo ( P < 0.001) and 5.2 months with chemotherapy ( P = 0.007); median OS was 18.7 versus 14.4 and 13.4 months ( P = 0.044 and 0.036), respectively. ORR was higher with triple-regimen (53.3% vs 25.0% and 28.1%), while DCR was 84.4%, 85.0%, and 73.4%. Grade 3–4 AEs occurred in 62.2%, 60.0%, and 56.3% of patients in the triple-regimen, ICIs-chemo, and chemotherapy groups, respectively; all toxicities were manageable and no treatment-related deaths occurred. The addition of locoregional treatment to sintilimab and lenvatinib was associated with favorable survival outcomes compared with chemotherapy-based first-line regimens, without a significant increase in the overall incidence of grade 3-4 AEs.This triple-regimen may represent a promising and well-tolerated first-line therapeutic option for patients with advanced ICC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.